CytRx Corporation
CYTR
Get informed when a big investor buys or sells
+ FollowMarket Cap$44.56M
Close$
Share Statistics
| Market cap | $44.56 Million |
|---|---|
| Enterprise Value | $939.10 Million |
| Dividend Yield | $10.46 (-) |
| Earnings per Share | $-3.21 |
| Beta | 2.1 |
| Outstanding Shares | 495,092,000 |
Return
| Return on Equity | 259.65% |
|---|---|
| Return on Assets | -2131.29% |
| Return on Invested Capital | 266.28% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.02 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.17 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.17 |
| Debt to Equity | -0.52 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About CytRx Corporation
2 employees
CEO: Steven Kriegsman LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists...